IN2014CN00570A - - Google Patents

Info

Publication number
IN2014CN00570A
IN2014CN00570A IN570CHN2014A IN2014CN00570A IN 2014CN00570 A IN2014CN00570 A IN 2014CN00570A IN 570CHN2014 A IN570CHN2014 A IN 570CHN2014A IN 2014CN00570 A IN2014CN00570 A IN 2014CN00570A
Authority
IN
India
Prior art keywords
therapy regimen
panitumumab
cetuximab
therapy
mutation
Prior art date
Application number
Inventor
Viladot Clara Montagut
Mestres Joan Albanell
Guerin Ana Rovira
Paricio Beatriz Bellosillo
Massegú Alba Dalmases
Original Assignee
Fundació Inst Mar Dinvestigacions Mèdiques Imim
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundació Inst Mar Dinvestigacions Mèdiques Imim filed Critical Fundació Inst Mar Dinvestigacions Mèdiques Imim
Publication of IN2014CN00570A publication Critical patent/IN2014CN00570A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

The invention relates to a new identified mutation in the epidermal growth factor receptor gene leading to an amino acidic change which highly correlates with the resistance to a therapy regimen comprising cetuximab and the sensitivity to a therapy regimen comprising panitumumab. The invention includes peptide sequences primers and probes to detect such a mutation as well as kits for predicting the response of a subject to a therapy regime comprising cetuximab and/or panitumumab. In particular the invention is useful in the therapy regimen applicable to metastasic colorectal cancer and to head and neck cancer.
IN570CHN2014 2011-08-03 2012-08-02 IN2014CN00570A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11382270A EP2554551A1 (en) 2011-08-03 2011-08-03 Mutations in the epidermal growth factor receptor gene
PCT/EP2012/065090 WO2013017645A1 (en) 2011-08-03 2012-08-02 Mutations in the epidermal growth factor receptor gene

Publications (1)

Publication Number Publication Date
IN2014CN00570A true IN2014CN00570A (en) 2015-04-03

Family

ID=46640020

Family Applications (1)

Application Number Title Priority Date Filing Date
IN570CHN2014 IN2014CN00570A (en) 2011-08-03 2012-08-02

Country Status (12)

Country Link
US (1) US9765399B2 (en)
EP (3) EP2554551A1 (en)
JP (1) JP6149034B2 (en)
KR (1) KR20140072035A (en)
CN (1) CN103717616B (en)
AU (1) AU2012292024A1 (en)
BR (1) BR112014002373A2 (en)
CA (1) CA2842270C (en)
ES (1) ES2556468T3 (en)
IN (1) IN2014CN00570A (en)
RU (1) RU2014107908A (en)
WO (1) WO2013017645A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8691231B2 (en) 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
EP3805404A1 (en) * 2014-05-13 2021-04-14 Board of Regents, The University of Texas System Gene mutations and copy number alterations of egfr, kras and met
MA39599A (en) 2014-05-14 2016-10-05 Merrimack Pharmaceuticals Inc Dosage and administration anti-egfr therapeutics
EP3428185A1 (en) * 2014-07-28 2019-01-16 Fundacio Institut mar d'Investigacions Médiques (IMIM) Mutations in the extracellular domain iii of epidermal growth factor receptor gene
CN104531854B (en) * 2014-11-10 2017-01-18 中国人民解放军第三〇七医院 Kit for detecting drug resistance of cetuximab used for metastatic colorectal cancer treatment by
AU2016252877A1 (en) * 2015-04-24 2017-11-09 Merrimack Pharmaceuticals, Inc. Methods of treating patients having mutations in the extracellular domain of epidermal growth factor receptor (EGFR) with a combination of three fully human monoclonal anti-EGFR antibodies
RU2626682C1 (en) * 2016-07-20 2017-07-31 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Method for predicting tumour resistance to tethegeth therapy of cetuximab in patients with plane-cellular language of language and multidisal bottom of the pta
CN111499749B (en) * 2020-03-13 2021-11-09 浙江大学 Cetuximab mutant and application thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007527241A (en) 2004-03-01 2007-09-27 ユニバーシティ オブ シカゴ Polymorphisms in the epidermal growth factor receptor gene promoter
TW200533339A (en) 2004-03-16 2005-10-16 Bristol Myers Squibb Co Therapeutic synergy of anti-cancer compounds
WO2006009694A2 (en) * 2004-06-14 2006-01-26 Imclone Sysetms Incorporated Crystal of egfr extracellular domain and cetuximab fab fragment and uses thereof
KR20070106029A (en) * 2005-02-24 2007-10-31 암젠 인코포레이티드 Epidermal growth factor receptor mutations
CN1737162A (en) * 2005-03-16 2006-02-22 南京中医药大学附属医院(江苏省中医院) EGF-R ELISA (EGFR) gene sequencing detection method
US7981606B2 (en) * 2005-12-21 2011-07-19 Roche Molecular Systems, Inc. Control for nucleic acid testing
AU2007329740B2 (en) * 2006-10-26 2014-05-01 Genentech, Inc. Genetic variations associated with tumors
AU2008205456A1 (en) 2007-01-18 2008-07-24 University Of Southern California Polymorphisms in the EGFR pathway as markers for cancer treatment
MX2009007987A (en) * 2007-01-25 2010-03-01 Dana Farber Cancer Inst Inc Use of anti-egfr antibodies in treatment of egfr mutant mediated disease.
US8137919B2 (en) * 2008-04-10 2012-03-20 Montefiore Medical Center Method of determining the sensitivity of cancer cells to EGFR inhibitors including cetuximab, panitumumab and erlotinib
GB2467691A (en) * 2008-09-05 2010-08-11 Aueon Inc Methods for stratifying and annotating cancer drug treatment options

Also Published As

Publication number Publication date
EP2739648B1 (en) 2015-09-16
CA2842270C (en) 2019-10-29
JP6149034B2 (en) 2017-06-14
EP2554551A1 (en) 2013-02-06
BR112014002373A2 (en) 2017-02-21
CN103717616B (en) 2016-06-29
EP2739648A1 (en) 2014-06-11
ES2556468T3 (en) 2016-01-18
EP2995623A1 (en) 2016-03-16
RU2014107908A (en) 2015-09-10
WO2013017645A1 (en) 2013-02-07
US9765399B2 (en) 2017-09-19
CN103717616A (en) 2014-04-09
JP2014521342A (en) 2014-08-28
AU2012292024A1 (en) 2014-02-27
KR20140072035A (en) 2014-06-12
US20140170662A1 (en) 2014-06-19
CA2842270A1 (en) 2013-02-07

Similar Documents

Publication Publication Date Title
IN2014CN00570A (en)
MX2019015016A (en) Assays for single molecule detection and use thereof.
HK1246360A1 (en) Method and kit for super-high-sensitivity measurement of protein and nucleic acid, and novel enzyme substrate
MX364410B (en) Method for detecting nucleosomes containing nucleotides.
PL2691771T3 (en) Aptamer coated measurement and reference electrodes and methods using same for biomarker detection
EP2776873A4 (en) Exploration method and system for detection of hydrocarbons
GB201317477D0 (en) Methods, compositions and kits for determing the presence/absnece of a variant nucleic acid sequence
EP3044323A4 (en) Compositions and methods for detecting and quantifying host cell protein in cell lines and recombinant polypeptide products
BR112014000443A2 (en) Methods and Nucleic Acids for Determining the Prognosis of an Individual with Cancer
ZA201301307B (en) Method for testing reheating crack sensitivity of dissimilar steel
IL236180A0 (en) Biomarker test for prediction or early detection of preeclampsia and/or hellp syndrome
WO2012096545A3 (en) Novel pancreatic cancer biomarker using the characteristics of pancreatic cancer stem cells, and use thereof
HK1181086A1 (en) Methods, probe sets, and kits for detection of deletion of tumor suppressor genes by fluorescence in situ hybridization
SG195256A1 (en) Alkylamino bodipy dyes as selective fluorescent probes for proteins andmouse embryonic stem cells
BR112013008255A2 (en) isolated antibody or functional fragment thereof, use of an isolated antibody or functional fragment thereof, pharmaceutical composition, polynucleotide, vector, transformed cell, and method for producing antibody
WO2012074904A3 (en) Methods and systems for evaluating the sensitivity or resistance of tumor specimens to chemotherapeutic agents
HK1133295A1 (en) Use of protein s100a12 as a marker for colorectal cancer s100a12
MX2013008252A (en) Prognostic signature for colorectal cancer recurrence.
AU2012236134A8 (en) Biomarkers for predicting sensitivity to cancer treatments
WO2014162008A3 (en) Biomarker signatures for predicting drug response in hodkin's lymphoma
MX2016011465A (en) Drimenol synthases and method for producing drimenol.
GB201206323D0 (en) Methods and arrays for use in the same
GB201016484D0 (en) Method
BR112017001474A2 (en) mutations in the extracellular domain iii of the epidermal growth factor receptor gene
SG10201500002XA (en) Rapid And Accurate Analysis Of Protein Sialylation